Vivacta Biotechnology has raised over US$50 million through its Series A and Series A+ funding rounds. The funding was led by Loyal Valley Capital and Decheng Capital, with support from investors like OrbiMed, Hankang Capital, Eisai Innovation, and others, including existing backers.
This strong investor interest shows confidence in Vivacta’s technology and future potential. The company will use the funds to speed up clinical development and expand its operations globally.
“We are deeply honored by the recognition and support from a group of leading investors”, commented Dr. Liu Yarong, Founder and CEO of Vivacta. “Vivacta is committed to advancing innovative in vivo CAR-T cell therapies. Our core product, GT801, has demonstrated promising safety and efficacy profiles in early clinical studies across hematological malignancies and autoimmune disease patients, potentially offering these patient populations a transformative treatment option to deliver innovative therapies to more patients in need.”
The company will use the new funding to continue clinical trials for its main project, GT801, and support its approval process. It will also expand its research team, improve its technology platform, and grow its business globally in the CAR-T field.
Vivacta recently shared early human trial results of GT801 at the American Society of Hematology Annual Meeting in December 2025. After the funding round, Xie Ronggang from Loyal Valley Capital and a partner from DC Global Ventures also joined the company’s board of directors.
Vivacta Biotechnology is a biotech company working on new types of CAR-T cell therapies. Its goal is to create better treatments for cancer and autoimmune diseases.
Its main product, GT801, is a next-generation therapy that has shown promising results in early clinical studies for treating blood cancers and autoimmune conditions.
Read More- Marloo raises $10 million in seed round led by Blackbird Ventures
